Affiliation:
1. Rostov State Medical University of the Ministry of Health Care of Russia
2. National Medical Research Centre for Oncology of the Ministry of Health Care of Russia
Abstract
Melanoma is a malignant tumor that can rapidly develop resistance to treatment because of its high mutational activity. The introduction of tyrosine kinase receptor inhibitors (BRAF, MEK) and cytotoxic T lymphocyte antigen/receptor inhibitors (CTLA4, PD-1) into clinical practice has led to an increase in patient survival rates. In in vitro studies, combining PIK3 and MEK inhibitors demonstrate a pronounced reduction in tumor cell growth. The phenomenon of synthetic lethality is also promising, allowing the high mutational load of melanoma to be used as a tool for the development of more effective drugs.
Publisher
Scientific Center for Biomedical Technologies of the Federal Medical-Biological Agency
Reference8 articles.
1. Kaprin A.D., Starinskii V.V., Shakhzadova A.O. Zlokachestvennye novoobrazovaniya v Rossii v 2021 godu (zabolevaemost' i smertnost'). M., MNIOI im. P.A. Gertsena — filial FGBU «NMITs radiologii» Minzdrava Rossii, 2022:252. [Kaprin A.D., Starinskii V.V., Shahzadova A.O. Zlokachestvennye novoobrazovaniya v Rossii v 2021 godu (zabolevaemost' i smertnost') [Malignant neoplasms in Russia in 2021 (morbidity and mortality)]. Moscow: National Medical Research Radiological Centre of the Ministry of Health Care of Russia, 2022:252. (In Russian)].
2. Assotsiatsiya onkologov Rossii, Assotsiatsiya spetsialistov po problemam melanomy, Obshcherossiiskaya obshchestvennaya organizatsiya «Rossiiskoe obshchestvo klinicheskoi onkologii». Melanoma kozhi i slizistykh obolochek: klinicheskie rekomendatsii. M., 2020. [Association of Oncologists of Russia, Russian Melanoma Professional Association “Melanoma. PRO”, Russian Society of Clinical Oncology. Melanoma kozhi i slizistykh obolochek: klinicheskie rekomendatsii [Melanoma of the skin and mucous: Clinical guidelines]. Moscow, 2020. (In Russian)].
3. Stukan' A.I., Goryainova A.Yu., Sharov S.V. Prichiny rezistentnosti k PARP-ingibirovaniyu i vozmozhnosti ee preodoleniya. Klinicheskii sluchai agressivnogo techeniya BRCA-assotsiirovannogo raka molochnoi zhelezy. Opukholi zhenskoi reproduktivnoi sistemy. 2022;18(1):54–65. [Stukan’ A.I., Goryainov A.Yu., Sharov S.V. Prichiny rezistentnosti k PARP-ingibirovaniyu i vozmozhnosti ee preodoleniya. Klinicheskiy sluchay agressivnogo techeniya BRCAassotsiirovannogo raka molochnoy zhelezy [Causes of resistance to PARP inhibitors and ways to overcome it. Case report of aggressive BRCA-related breast cancer]. Opukholi zhenskoy reproduktivnoy sistemy [Tumors of female reproductive system]. 2022;18(1):54–65. (In Russian)]. DOI: 10.17650/1994-4098-2022-18-1-54-65.
4. Hartman G.D., Lambert-Cheatham N.A., Kelley M.R., Corson T.W. Inhibition of APE1/Ref-1 for neovascular eye diseases: From biology to therapy. Int. J. Mol. Sci. 2021;22(19):10279. DOI: 10.3390/ijms221910279.
5. Lelliott E.J., McArthur G.A., Oliaro J., Sheppard K.E. Immunomodulatory effects of BRAF, MEK, and CDK4/6 inhibitors: Implications for combining targeted therapy and immune checkpoint blockade for the treatment of melanoma. Front. Immunol. 2021;12:661737. DOI: 10.3389/fimmu.2021.661737.